Last reviewed · How we verify
IPX066
IPX066 is an extended-release formulation of levodopa and carbidopa designed to provide more consistent dopamine replacement in the brain over an extended period.
IPX066 is an extended-release formulation of levodopa and carbidopa designed to provide more consistent dopamine replacement in the brain over an extended period. Used for Parkinson's disease with motor fluctuations.
At a glance
| Generic name | IPX066 |
|---|---|
| Also known as | ER CD-LD, extended-release carbidopa-levodopa |
| Sponsor | Impax Laboratories, LLC |
| Drug class | Dopamine replacement therapy; extended-release levodopa/carbidopa combination |
| Target | Dopamine pathway (via levodopa conversion to dopamine) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
IPX066 combines levodopa (a dopamine precursor) with carbidopa (a decarboxylase inhibitor that prevents premature conversion of levodopa in the periphery) in a multi-layer extended-release tablet. This formulation aims to reduce motor fluctuations and improve symptom control in Parkinson's disease patients by maintaining more stable plasma levels of levodopa throughout the day compared to immediate-release formulations.
Approved indications
- Parkinson's disease with motor fluctuations
Common side effects
- Dyskinesia
- Nausea
- Dizziness
- Headache
- Orthostatic hypotension
Key clinical trials
- Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease (PHASE2)
- Montelukast in Parkinson Disease (PHASE2, PHASE3)
- Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease (PHASE3)
- Dopaminergic Dysfunction in Late-Life Depression (PHASE2)
- Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease. (PHASE1, PHASE2)
- Dopaminergic Therapy for Anhedonia - 2 (PHASE4)
- Long-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's Disease
- Fexofenadine as Adjuvant Therapy in Parkinson Disease (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |